All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Expression Profiles and Mechanisms of microRNAs in Prostate Cancer

Song C1*, Chen H2 and Chunyu S3

1Medical Research Center, Shaoxing People’s Hospital, Shaoxing, Zhejiang province, China

2Zhejiang Institute of Microbiology/Key Laboratory of Microorganism Technology and Bioinformatics Research of Zhejiang Province, Hangzhou, Zhejiang, China

3The Department of Anesthesia, the Second Clinical Hospital of Harbin Medical University, Harbin, Heilongjiang province, China

*Corresponding Author:
Chunjiao Song
Medical Research Center, Shaoxing People’s Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, Zhejiang province, China.
Tel: 86057588228687
E-mail: [email protected]

Received date: July 02, 2018; Accepted date: July 12, 2018; Published date: July 20, 2018

Citation: Song C, Chen H and Chunyu S (2018) Expression Profiles and Mechanisms of microRNAs in Prostate Cancer. Biomark J. 4:13. doi: 10.21767/2472-1646.100051.

 
Visit for more related articles at Biomarkers Journal

Abstract

MicroRNAs are small non-coding RNA molecules with a length of 20 to 25 nucleotides. As gene expression regulators, microRNAs can completely or not completely complementarily bind with mRNA to inhibit translation or degradate mRNA. Aberrant expression of microRNAs is closely related to the occurrence, development, metastasis and prognosis of prostate cancer. Some microRNAs may promote cancerization, while others are tumor suppressors. In this review, we summarized the expression profiles of microRNAs in recent years, in particular, the data obtained by large-scale high-throughput technologies. We also summed up microRNAs which had the potential to be biomarkers of prostate cancer, and the mechanisms of microRNAs in the developmental progression of prostate cancer. The review provided medical and scientific researchers with an overview of the status and role of microRNAs in prostate cancer. In short, we summarized the expression profiles of microRNAs discovered in recent years and their roles and mechanisms in the occurrence and development of prostate cancer.

Keywords

Meta-MicroRNAs; Prostate cancer; Expression profile; Biomarker

Introduction

Prostate cancer (PCa) is a high incidence of male reproductive system malignancy all over the world. In 2017; 161,360 new cases were reported, and 26,730 patients died from PCa in America [1]. In China, the incidence of PCa and the threat to men's health are also increasing. At present, PSA (prostate specific antigen) test was most widely used to screen PCa patients in clinical practice, combined with imageological examination and fine needle puncture to diagnose PCa. For low-risk PCa, the treatment strategies were closely monitor and active surveillance. For patients with high-risk PCa, options were radical prostatectomy (RP), radiation therapy, and androgen deprivation therapy (ADT). However, in the advanced cases of castration resistance and metastases, patients would receive chemotherapy. Nowadays, nanoparticle delivery system has attracted great attention from the scientific community. Nanoparticles display infinite potential to increase anti-tumor efficacy of highly hydrophobic chemotherapeutic drugs, which makes them more attractive to provide the opportunities in targeted drug delivery [2,3].

microRNAs (miRNAs) are small conserved endogenous noncoding RNAs with the length of 20-25 nt, which regulate target genes by complementarily binding to the 3’-untranslated regions (UTR) of target mRNAs. It was estimated that each miRNA could regulate hundreds of target genes, and each mRNA could be bound by hundreds of different miRNAs. So, about 60% of coding genes were regulated by miRNAs encoded by 1% of human genome [4]. Nowadays, more than 4800 human mature miRNAs were reported in miRBase v22 (http://www.mirbase.org/). miRNAs may effect a wide variety of cellular processes, such as cell proliferation, differentiation, and apoptosis, etc. miRNAs may also participate in multiple cellular pathways in a variety of solid tumors by dual roles: Oncogenic miRNAs or tumor suppressor miRNAs.

The goals of this review are to summarize the expression profiles of microRNAs in PCa, and to identify the predictive biomarkers which may isolate the lethal or drug-resistant patients to reduce overtreatment and to improve personalized treatment effect.

The Expression Profiles Of Micrornas In Prostate Cancer

Previously, we scanned the miRNAs expression profiles in highrisk and low-risk PCa tissue samples using the second-generation sequencing and quantitative real-time PCR (qRT-PCR) technology [5]. The obtained results were summarized in Table 1 together with other literatures’ data [6,7]. Some of these miRNAs expression were controversial in different studies, while others were consistent in tissue and body fluid specimens, which were all marked in Table 1. Obviously, miRNAs with consistent results reported in all literatures could provide more valuable information. For example, miR-26a, miR-106a and miR-141 were up-regulated in PCa tissues and serum samples. In addition, the gene encoded a sort of miRNA may produce multiple mature miRNA products due to different splicing processes, and they often have the same target genes and synergistic effects. Currently, there were more than 300 miRNAs differentially expressed in PCa tissues, and 49 miRNAs detected in serum, 4 in urine samples (Table 1). These differentially expressed data were collected from different studies screening various prostate samples, such as prostate cancer (PCa), benign prostate controls, castration resistance prostate cancer (CRPC) and hormone sensitive PCa, and metastatic PCa, etc.

Items Tissue Serum Urine
High-expression micro-RNAs let-7a^/c miR-7/7a* miR-9# miR-10b miR-15b^ miR-16^# miR-17-5p miR-20a/b# let-7i miR-9* miR-16# miR-615-3p
miR-21^# miR-22^ miR-26a^# miR-27a^# miR-28-3p miR-29b^ miR-30a*/d^/e* miR-31^#/-5p^ miR-20b# miR-26a# miR-34b# miR-4316
miR-32 miR-33a^ miR-34/a^#/c^ miR-92^ miR-93^# miR-96^ miR-100^# miR-101^ miR-92a/b miR-93# miR-100# -
miR-106/a^#/b miR-122 miR-125b^#/b-5p/-2# miR-126^#/-5p^ miR-129^ miR-135b# miR-138 miR-141#/-3p miR-103 miR-106a# miR-107 -
miR-143^# miR-144/* miR-146b miR-148a/b miR-150 miR-151a-5p miR-153 miR-154* miR-125b# miR-139-5p miR-141# -
miR-155 miR-181b^ miR-182#/*/-5p# miR-183 miR-184^ miR-191 miR-193/a-5p miR-194 miR-143# miR-195# miR-197# -
miR-198^ miR-200b-3p/c^# miR-203^# miR-205-5p^ miR-210# miR-212^ miR-215 miR-216a miR-200a/b/c# miR-205 miR-209 -
miR-218^ miR-221^#/-3o miR-222#/-3p miR-301a^# miR-302^ miR-335^/* miR-338# miR-370 miR-210# miR-221# miR-223# -
miR-373 miR-374a/*/b miR-375# miR-379 miR-423-5p miR-483-5p miR-486-5p^# miR-542-3p miR-328 miR-375# miR-485-3p -
miR-556-5p miR-592 miR-615^ miR-629* miR-650 miR-663 miR-671 miR-940 miR-486-5p# miR-516-3p miR-574-3p -
miR-1260b miR-1301/-3p miR-1307 miR-1323 miR-17-92^ miR-99 cluster^ miR-106b-25 miR-183 cluster miR-636 miR-640 miR-766 -
- - - - - - - - miR-874 miR-885-5p miR-1207-5p -
- - - - - - - - miR-1274a - - -
Low-expression micro-RNAs let-7a^/d#/g miR-1 miR-7-1* miR-8 miR-15b^ miR-16^ miR-17/-3p miR-21^# miR-15a/16-1 miR-24# miR-26b# miR-205#
miR-22^ miR-23a#/b miR-24# miR-25 miR-26a^/a-5p/b# miR-27/a^# miR-28-5p miR-29a/b^/c miR-30c miR-107# miR-129# miR-214
miR-30d^ miR-31^#/-5p^ miR-33a^ miR-34a^#/b#/c^/c-5p miR-92^ miR-93^ miR-96^ miR-98 miR-223# - - -
miR-100^ miR-101^ miR-106a^ miR-107# miR-124# miR-125/a-3p/b^# miR-126^#/*/-5p^ miR-128/a - - - -
miR-129^# miR-130b miR-132 miR-133b# miR-140 miR-143^ miR-145#/-5p# miR-146a - - - -
miR-148# miR-149 miR-151a-3p miR-152/-3p miR-154 miR-181b^/b-1#/c# miR-184^ miR-186 - - - -
miR-187 miR-190a miR-192 miR-193b miR-195 miR-196b miR-198^ miR-199
a/a-3p/b
- - - -
miR-200/b/b*/c^# miR-203^# miR-204 miR-205#/-5p^ miR-206 miR-212^ miR-218^ miR-219-5p - - - -
miR-221^# miR-223^ miR-224 miR-296-5p miR-301/a^#/b miR-320^/a# miR-331-3p miR-335^ - - - -
miR-339-5p miR-376c miR-378 miR-432 miR-449a# miR-452/-5p miR-486-5p^# miR-490 - - - -
miR-491-5p# miR-493-3p/5p miR-494 miR-503 miR-511-3p miR-519d/-3p miR-520h miR-532-3p - - - -
miR-542-5p miR-564 miR-605 miR-615^ miR-628-5p miR-631 miR-875-5p miR-1256 - - - -
miR-1207-3p# miR-1271 miR-1296 miR-3619-5p miR-1-133a miR-17-92a^ miR-99 cluster^ miR-200
cluster
- - - -
miRNA in CRPC miRNA in ADPC High- expression in metastatic Pca let-7f miR-21# miR-27h miR-100/-5p miR-122a miR-125b^# miR-133b# miR-141^# miR-141# miR-375# miR-378* -
miR-145# miR-154* miR-181a miR-184^ miR-195 miR-196a/b-3p miR-221# miR-222^# - - - -
miR-361/-5p miR-383 miR-424 miR-487 miR-488# miR-582-5p miR-616 miR-23b-24 - - - -
    High- expression in metastatic Pca let-7/c# miR-17-5p miR-19b miR-20a miR-29b miR-34 miR-92a miR-125b^# miR-409-3p - - -
miR-128b miR-141^# miR-145-3p#/-5p# miR-146a/b miR-148a miR-184^ miR-198 miR-200
b-3p/c
- - - -
miR-205 miR-222^# miR-331-3p miR-663 miR-3654 miR-4638-5p miR-4735-3p miR-106b-25 - - - -
let-7c# miR-10 miR-24 miR-26 miR-27 miR-30c miR-100^ miR-125b# miR-451 - - -
miR-126# miR-129-3p miR-141# miR-152 miR-181/a^/b-1#/c# miR-210-3p# miR-218 miR-221# - - - -
miR-222# miR-224 miR-338# miR-409-3p/-5p miR-543 miR-590-5p miR-1247-5p miR-106b-25 - - - -
  Low- expression in metastatic PCa miR-1 miR-21 miR-23b miR-27b miR-29b miR-30b-3p/d-5p miR-33a miR-34b# - - - -
miR-96 miR-100^ miR-133a miR-135a-1/b# miR-141#/-3p miR-143 miR-145# miR-146a - - - -
miR-154 miR-181a/b miR-182# miR-183 miR-188-5p miR-193a miR-200/a/b/c# miR-203# - - - -
miR-205 miR-373 miR-429 miR-449a# miR-486-5p# miR-508-5p miR-520c miR-573# - - - -
miR-618 miR-675 - - - - - - - - - -

Table 1: The expression profile of microRNAs in prostate cancer.

Following the rapid development of new high-throughput technologies, such as whole-genome analysis, deep sequencing and microarray, in particular, single-cell genome/transcriptome sequencing, researchers may get the miRNAs expression data in specific time and space from these large-scale analyses.

microRNAs as biomarkers for prostate cancer

At present, a lot of studies have focused on the correlation between specific miRNA expression level and various clinical features of PCa, such as tumor stage, Gleason score, metastasis, biochemical recurrence and disease specific death, etc. We also conducted a meta-analysis to evaluate the application value of miRNAs as PCa biomarkers. Our results supported that miRNAs might distinguish the different states of PCa and predict the prognosis of PCa [8]. About 180 miRNAs related to the prognosis, recurrence and metastasis of PCa have been found and summarized in Table 2.

Items Tissue Serum Urine
Diagnosis let-7a/b miR-16# miR-21# miR-23b miR-96 miR-106a miR-141# miR-149 let-7c# miR-15a/16-1# miR-19/b-3p miR-145#
miR-150 miR-182# miR-185# miR-187 miRNA-200c# miR-205# miR-221# miR-222# miR-21# miR-30c miR-34b# miR-193b
miR-224 miR-452 miR-551 miR-663 miR-1274 miR-2909# miQ miR-130b-301b miR-129 miR-139-5p miR-141# miR-205#
- - - - - - - - miR-151-3p miR-200a/b/c# miR-203 miR-214#
- - - - - - - - miR-205# miR-214# miR-297# -
- - - - - - - - miR-320a#/b/c miR-345 miR-375# -
- - - - - - - - miR-519c-5p miR-2909# - -
Gleason score let-7a-1/a/f miR-9# miR-15b miR-16 miR-21# miR-24 miR-26a miR-29a* miR-19a# miR-20a miR-21# -
miR-30d miR-31# miR-33 miR-34a* miR-93 miR-96 miR-106a miR-125b# miR-141# miR-200b miR-221# -
miR-126* miR-132 miR-143 miR-145# miR-152 miR-182# miR-195 miR-205 miR-375# miR-451# - -
miR-221# miR-222# miR-296 miR-331-3p miR-342-3p miR-425* miR-451# miR-551a - - - -
miR-622 miR-708 miR-106b-25 - - - - - - - - -
  Treatment miR-18a-5p miR-21# miR-23b miR-27b miR-24 miR-29b miR-34a# miR-143 - - - -
miR-199a miR-200c# miR-210 miR-146a miR-375# miR-491-5p# miR-17-92 - - - - -
      Prognosis let-7b miR-1 miR-10b miR-15/b miR-16 miR-21# miR-23b miR-24 miR-15a/16-1 miR-129 miR-146b-3p -
miR-30d miR-31# miR-34b# miR-96 miR-100 miR-106b miR-133b# miR-135a/b# miR-152 miR-194# miR-375# -
miR-143 miR-151-3p miR-182#/-5p# miR-183 miR-187 miR-188-5p miR-194# miR-200a miR-1290# - - -
miR-205 miR-210 miR-221# miR-222# miR-224 miR-301a# miR-331-3p miR-375# - - - -
miR-429 miR-449b# miR-452 miR-511-3p miR-516-3p miR-708 miR-711 miR-940 - - - -
miR-1207-3p# miR-2909# miR-4638-5p miQ miR-106b-25 - - - - - - -
  Metastasis let-7c# miR-1 miR-16 miR-31# miR-32 miR-33 miR-34a#/b# miR-126* miR-194 miR-628-5p - -
miR-141-3p miR-143 miR-145# miR-154* miR-181a miR-195 miR-205 miR-379 - - - -
miR-409-3p/-5p miR-518f-5p miR-573# miQ - - - - - - - -

Table 2: MicroRNAs as biomarkers in prostate cancer.

miRNAs were good biomarkers because they not only could noninvasively identify PCa, but also were stable in a variety of samples and could be detected in a variety of methods. In Table 2, we found that the miRNA biomarkers in serum, especially urine samples, were still insufficient, which would be the direction of scientific researchers' efforts. In addition, a large number of studies have begun to focus on multiple miRNAs combined with other indicators to jointly predict PCa and its prognosis, such as PSA (prostate specific antigen), PCA3 (prostate cancer antigen 3) and fusion gene TMPRSS2-ERG, etc. In Table 2, the miQ index was invented by Larne et al. [9]. It could differentiate PCa accurately and had the potential to predict prognosis [9]. This was also an effective strategy to avoid high heterogeneity of PCa.

THE Mechanism Of Micrornas In Prostate Cancer Progression

Most miRNAs are transcribed by RNA polymerase II, processed by Drosha and Dicer, and transported out of the nucleus by Exportin-5 during this period. Finally, the mature miRNAs become the 18-25 nt duplexes, assembled into the RNA-induced silencing complex (RISC). Moreover, most mature miRNAs combine with the 3’-UTR of the target messenger RNA, a few mature miRNAs bind to 5’- UTR. Some studies have shown that miRNAs can also combined to the coding regions or the specific sequence promoter of target genes [10-12].

The Mechanism Of Abnormal Expression Of Mirnas In Prostate Cancer

miRNAs have dual functions: oncogenic miRNAs can activate carcinogenesis, tumor suppressor miRNAs can inhibit tumor progression. Among them, carcinogenic miRNAs are usually highly expressed in PCa, while tumor suppressor miRNAs are down-regulated. In high-risk PCa and CRPC (Castration Resistant Prostate Cancer), the expression of Dicer and Drosha/DGCR8 was significantly increased, which contributed to the processing and up-regulated the expression of oncogenic miRNAs [13,14]. On the contrary, Drosha or Dicer expression decreased would attenuate mature miRNA biogenesis [15,16]. Myc could inhibit the binding of miR-26a/b to RNA polymerase II, thus affecting its transcription [17].

On the other hand, the genes that encoded tumor suppressor miRNAs were deleted in 60% of PCa samples [18,19]. Mutations or polymorphisms of tumor suppressor miRNAs might also lead to down-regulation of their expression, and increase the susceptibility to PCa [20,21]. In addition, methylation of the promoters of tumor suppressor miRNAs also reduced their expression, increasing the risk of PCa [22-24].

In addition to the above mentioned mechanisms leading to abnormal miRNAs expression, it was worth mentioning that the absence or variation of target genes was also one of the important reasons for the development of PCa. Feng et al. found that the C/T polymorphism of BMPRlB located in the 3'-UTR of this gene where was the binding site of miR-125b, could cause miR-125b not to bind to this region and lose its regulatory role, increasing the risk of cancer [25,26].

Micrornas Associated With Androgen Receptor Signaling Pathways

Early clinical PCa was mostly androgen-sensitive, but some of these cases would progress to incurable CRPC or metastatic PCa after initial treatment or ADT. These suggested that androgen receptor (AR) played an important role in the evolution of PCa. AR is a nuclear hormone receptor as a transcription factor to regulate the expression of a large number of downstream target genes. Previously, we had reviewed miRNAs related to AR signaling pathways [27]. In the review, we had not only summarized many miRNAs regulated by AR, but also gathered the miRNAs that directly and indirectly regulated AR [27].

Ostling et al. detected 71 miRNAs in a large sample study that affected AR expression levels by binding to AR 3’-UTR region of 6 Kb length [28]. miR-135b, miR-147, miR-34a, miR-644, miR-297, miR-298, miR-299-3p, miR-371-3p, miR-421, miR-449/b, miR- 491-5p and miR-876-3p reduced AR mRNA levels, and miR-488 decreased AR protein levels, while miR-644 increased AR mRNA levels [28]. In addition, other research groups found that miR-34b [18], miR-124 [29], miR-145 [30], miRNA-221/222 [14], miR-301a [31], miR-320a [32] and miR-449a [33] could directly regulate AR expression and AR signaling pathway activity. miR-31 bound to the coding region of AR gene, which was usually mutated in PCa [34]. miR-1207-3p indirectly regulated AR activity through direct target molecule FNDC1 to form a new miR-1207-3p/FNDC1/FN1/ AR pathway in PCa [35]. miR-185 could indirectly attenuate AR function by inhibiting BRD8 ISO2 [36]. Furthermore, miR-2909 and AR regulated each other to structure a positive feedback loop [37], while a negative feedback loop was formed between miR- 124 and AR [38].

In addition to the above mentioned miRNAs that regulated AR, there were many miRNAs that were regulated by AR. Androgen could stimulate a variety of miRNAs expression, such as: miR-21 [39], miR-23a, miR-24-2, miR-27a [40], miR-19a, miR-133b [41], miR-125b [42], miR-148 [43], miR-182-5p [44], miR-126, miR- 181b-l, miR-181c, miR-221, miR-338 [45] and miR-421 [46], and so on, androgen responsive element (ARE) might exist in these miRNAs flanking sequences. AR could also inhibit or activate the expression of miR-99a, let-7c and miR-125b-2 by chromatin remodeling factors: EZH2 or JMJD3 [47]. In addition, let-7d [48], miR-10a, miR-141, miR-15* and miR-1225-5p [49], were regulated by androgen.

MicroRNAs associated with metastatic prostate cancer and CRPC

Metastasis and castration resistance were two characteristics of advanced PCa. EMT (epithelial to mesenchymal transition) was the important performance of metastasis, while MET (mesenchymal to epithelial transition) was the phenotype of benign reversion of PCa. The researchers commonly used interdermal markers: fibronectin, ZEBl, ZEB2, vimentin, ZO1, snail and epithelial marker: E-cadherin, to monitor the occurrence and development of metastasis.

Osthole, a coumarin extracted from medicinal plants, inhibited EMT and metastasis by down-regulating the expression of miR- 23a-3p to reduce E-cadherin expression and Snail DNA-binding ability [50]. Snail was also confirmed to be the target gene of miR- 486-5p [51], miR-182 and miR-203 [52]. The members of miR- 200 family, miR-200c and miR-141, inhibited JAGGEDl protein expression, and further regulated ZEB1 which was a mesothelial marker [22]. miR-210-3p participated in NF-κB signaling via targeting TNIP1 and SOCS1 to trigger EMT, migration and bone metastasis [53]. miR-9 was an oncomiR targeting E-cadherin [54], while miR-573 was a tumor suppressor to directly target FGFR1 gene [55].

So far, metastatic castration-resistant prostate cancer (mCRPC) is considered incurable. miRNAs may play an important role in the malignant transformation process of PCa to this terminal stage. There was study finding that miRNA-221/222 was up-regulated in CRPC [14]. miR-145-5p and miR-145-3p were down-regulated in CRPC, and miR-145-3p had four downstream target genes: MELK, NCAPG, BUB1, and CDK1 [56]. In addition, miR-1290 and miR-375 might be the potential prognostic biomarkers for CRPC patients in exosomes [57].

Conclusion

As a group of small non-coding RNA molecules, microRNAs, combined with long non-coding RNAs, jointly regulate complex signal networks with different mechanisms. Are they subordinate or dominant in the occurrence and development of PCa? What are the mechanisms by which they contribute to PCa? These questions are far from being answered by researchers. We still need a lot of further researches to reveal the rules, and to provide the powerful theoretical basis for early diagnosis, prognosis prediction and targeted treatment for PCa.

Acknowledgement

This work was supported by Zhejiang Provincial Science Technology Program of China (2013C33101), Zhejiang Medical Platform Program (2015RCA023), and Shaoxing municipal health and family planning science and technology innovation project (2017CX004).

References

Select your language of interest to view the total content in your interested language

Viewing options

Post your comment

Share This Article

Flyer image
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh